Dusseldorf - Delayed Quote EUR

Cidara Therapeutics Inc (20D.DU)

9.19 +8.73 (+1,900.00%)
At close: April 23 at 7:30 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 20D.DU

Recent News: 20D.DU

View More
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
GlobeNewswire yesterday
Cidara buys back rights to flu therapy from J&J for $85m

Cidara buys back rights to flu therapy from J&J for $85m
Pharmaceutical Technology 2 days ago
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
GlobeNewswire 3 days ago
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
GlobeNewswire 3 days ago
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 5 days ago
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
GlobeNewswire 5 days ago
Cidara Therapeutics Announces Reverse Stock Split

Cidara Therapeutics Announces Reverse Stock Split
GlobeNewswire 5 days ago
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire 22 days ago
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire last month
Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio

Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
GuruFocus.com 2 months ago
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
GlobeNewswire 2 months ago
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
GlobeNewswire 2 months ago
View More

Related Tickers

ALGS Aligos Therapeutics, Inc.
0.7820
-4.40%
 
INZY Inozyme Pharma, Inc.
4.4400
+2.54%
 
HOOK HOOKIPA Pharma Inc.
0.8933
+10.82%
 
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
EFTR eFFECTOR Therapeutics, Inc.
1.8900
+4.42%
 
PDSB PDS Biotechnology Corporation
3.2700
+0.31%
 
ARDX Ardelyx, Inc.
6.42
+1.74%
 
HRTX Heron Therapeutics, Inc.
2.4500
-3.92%
 
VKTX Viking Therapeutics, Inc.
74.31
+7.91%